Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428984 | 0.90 | SIGMAR1 (0.57) | SIGMAR1DRD2DRD4OPRM1DRD3 | |
| SCHEMBL12500369 | 0.89 | SIGMAR1 (0.66) | SIGMAR1DRD2DRD4OPRM1DRD3 | |
| SCHEMBL7859218 | 0.89 | SIGMAR1 (0.70) | SIGMAR1DRD2DRD4DRD3KCNH2 | |
| SCHEMBL12500566 | 0.87 | SIGMAR1 (0.67) | SIGMAR1DRD2DRD4OPRM1DRD3 | |
| SCHEMBL11800470 | 0.85 | SIGMAR1 (0.72) | SIGMAR1 | |
| SCHEMBL283735 | 0.82 | SIGMAR1 (0.81) | SIGMAR1GAAMAPTKCNH2CA12 | |
| SCHEMBL2238594 | 0.82 | CA12 (0.57) | SIGMAR1DRD2DRD4OPRM1DRD3 | |
| SCHEMBL421501 | 0.82 | MEN1 (0.64) | SIGMAR1DRD4GAAMAPT | |
| SCHEMBL12500393 | 0.81 | SIGMAR1 (0.70) | SIGMAR1DRD2DRD4DRD3KCNH2 | |
| SCHEMBL8140699 | 0.80 | SIGMAR1 (0.77) | SIGMAR1GAAMAPTKCNH2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| CN-111056974-A | Preparation method of N-cyanoethyl-N-phenethylaniline | 烟台安诺其精细化工有限公司 | 2020-04-24 | — | — | CN | disclosed |
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-12 | — | — | US | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1210335-B1 | AMINOCARBONYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, METHOD FOR PRODUCING SAME AND THE USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-14 | — | — | EP | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| US-6512000-B1 | Aminocarbonyl- substituted benzimidazole derivatives for the treatment of diseases in which inhibition of tryptase is of therapeutic such as for treating an inflammatory or allergic disease | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-28 | — | — | US | disclosed |
| US-5068064-A | Antiseptics, microbiocides or antiseptics | SANOFI (FR) | 1991-11-26 | — | — | US | disclosed |
| EP-0086450-B1 | SUBSTITUTED PHENYLPYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, MEDICINES BASED ON THESE COMPOUNDS AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-05-28 | — | — | EP | disclosed |
| EP-0086450-A2 | Substituted phenylpyrazole derivatives, process for their preparation, medicines based on these compounds and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204160-A1 | SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF | PSEN1, PSEN2, BACE1 | SIGMAR1 1872/4885DRD2 760/4885DRD4 200/4885 |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | SIGMAR1 694/4885DRD2 3601/4885DRD4 3998/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | SIGMAR1 694/4885DRD2 3601/4885DRD4 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.